SOURCE: Cytovance Biologics

Cytovance Biologics

April 26, 2016 05:00 ET

Cytovance Biologics, Inc Announces New Hire Francis Maddalo as Sr. Vice President of Manufacturing

OKLAHOMA CITY, OK--(Marketwired - April 26, 2016) - Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization specializing in the production of therapeutic proteins and antibodies from mammalian cell culture and microbial fermentation, today announced the addition of Francis (Frank) Maddalo as Sr. Vice President of Manufacturing. Mr. Maddalo will oversee Cytovance's Manufacturing & Warehouse functions.

Frank Maddalo has over 30 years' experience manufacturing commercial cGMP products, including extensive manufacturing operations expertise extending from small molecule drugs to biologics and medical devices. Frank established and operated multiple cGMP commercial-scale manufacturing facilities in the United States, Australia, The Netherlands, Wales, and Switzerland. He produced and brought to market multiple products, including Artificial Skin, FSH, LH, HgH, and holds several patents for commercialized collagen products. Prior to Cytovance, Frank was Vice President Operations/Manufacturing at Perosphere, Inc. where he completed the construction of a 20,000 sq ft API manufacturing facility for small molecule Drug Substance and Drug Product, including compounding, fill finish, packaging, labeling, shipping and storage. Frank commissioned and qualified the facility/utilities and validated all process operations and processes including Tech Transfer from R&D/CMO sites to in-house. His previous experience includes DSM Biologics, CR Bard, Serono Labs, and Verax Biomedical. At DSM Frank was directly responsible for the staffing and start-up of a 80,000 sq ft multiproduct biologics facility in Brisbane, Australia. The facility was designed to comply with all local /federal regulations (Australian) as well as the EMA and FDA. As part of the Biologics executive team Frank was responsible for the production of biologics, GMP compliance/training, QBD, operational excellence, applied process development, safety and project management.

Frank holds a B.S. in Biology from the University of Massachusetts, Boston and an M.S. in Physiology/Virology from Northeastern University.

"Frank is the ideal candidate for this position. His extensive experience with both clinical and commercial biologics manufacturing, along with his years of working in process development and validation with site qualifications, makes him an invaluable asset to Cytovance's Leadership team," said CEO Darren Head.

"I am honored to be recognized by Darren Head, President and CEO of Cytovance," said Frank Maddalo, "I have the benefit of working with an incredibly talented organization with standout performers at every level. I look forward to working with our executive team, the operations leadership team, the quality unit, and our gifted employees as we continue into the next phase of the company's evolution. Combining all of the 'execution' facets of the Cytovance organization under one umbrella will improve performance, reduce silo effects, and ultimately provide a better customer experience."

Contact Information

  • Contact Information
    Cheryl Soerensen
    Marketing Communications Manager
    Email contact